Literature DB >> 27872149

Endogenous Telomerase Reverse Transcriptase N-Terminal Tagging Affects Human Telomerase Function at Telomeres In Vivo.

Kunitoshi Chiba1, Jacob M Vogan1, Robert A Wu1, Manraj S Gill1, Xiaozhu Zhang1, Kathleen Collins1, Dirk Hockemeyer2.   

Abstract

Telomerase action at telomeres is essential for the immortal phenotype of stem cells and the aberrant proliferative potential of cancer cells. Insufficient telomere maintenance can cause stem cell and tissue failure syndromes, while increased telomerase levels are associated with tumorigenesis. Both pathologies can arise from only small perturbation of telomerase function. To analyze telomerase at its low endogenous expression level, we genetically engineered human pluripotent stem cells (hPSCs) to express various N-terminal fusion proteins of the telomerase reverse transcriptase from its endogenous locus. Using this approach, we found that these modifications can perturb telomerase function in hPSCs and cancer cells, resulting in telomere length defects. Biochemical analysis suggests that this defect is multileveled, including changes in expression and activity. These findings highlight the unknown complexity of telomerase structural requirements for expression and function in vivo.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  CRISPR/Cas9; embryonic stem cells; genome editing; pluripotent stem cells; telomerase; telomeres

Mesh:

Substances:

Year:  2017        PMID: 27872149      PMCID: PMC5247607          DOI: 10.1128/MCB.00541-16

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  69 in total

1.  TIN2, a new regulator of telomere length in human cells.

Authors:  S H Kim; P Kaminker; J Campisi
Journal:  Nat Genet       Date:  1999-12       Impact factor: 38.330

2.  PTOP interacts with POT1 and regulates its localization to telomeres.

Authors:  Dan Liu; Amin Safari; Matthew S O'Connor; Doug W Chan; Andrew Laegeler; Jun Qin; Zhou Songyang
Journal:  Nat Cell Biol       Date:  2004-06-06       Impact factor: 28.824

3.  Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations.

Authors:  Frank Soldner; Josée Laganière; Albert W Cheng; Dirk Hockemeyer; Qing Gao; Raaji Alagappan; Vikram Khurana; Lawrence I Golbe; Richard H Myers; Susan Lindquist; Lei Zhang; Dmitry Guschin; Lauren K Fong; B Joseph Vu; Xiangdong Meng; Fyodor D Urnov; Edward J Rebar; Philip D Gregory; H Steve Zhang; Rudolf Jaenisch
Journal:  Cell       Date:  2011-07-14       Impact factor: 41.582

Review 4.  The role of double-strand break repair pathways at functional and dysfunctional telomeres.

Authors:  Ylli Doksani; Titia de Lange
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-09-16       Impact factor: 10.005

Review 5.  Induced Pluripotent Stem Cells Meet Genome Editing.

Authors:  Dirk Hockemeyer; Rudolf Jaenisch
Journal:  Cell Stem Cell       Date:  2016-05-05       Impact factor: 24.633

6.  Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells.

Authors:  X Yi; J W Shay; W E Wright
Journal:  Nucleic Acids Res       Date:  2001-12-01       Impact factor: 16.971

7.  A homozygous telomerase T-motif variant resulting in markedly reduced repeat addition processivity in siblings with Hoyeraal Hreidarsson syndrome.

Authors:  Maria M Gramatges; Xiaodong Qi; Ghadir S Sasa; Julian J-L Chen; Alison A Bertuch
Journal:  Blood       Date:  2013-03-28       Impact factor: 22.113

8.  The POT1-TPP1 telomere complex is a telomerase processivity factor.

Authors:  Feng Wang; Elaine R Podell; Arthur J Zaug; Yuting Yang; Paul Baciu; Thomas R Cech; Ming Lei
Journal:  Nature       Date:  2007-01-21       Impact factor: 69.504

9.  Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells.

Authors:  Luis F Z Batista; Matthew F Pech; Franklin L Zhong; Ha Nam Nguyen; Kathleen T Xie; Arthur J Zaug; Sharon M Crary; Jinkuk Choi; Vittorio Sebastiano; Athena Cherry; Neelam Giri; Marius Wernig; Blanche P Alter; Thomas R Cech; Sharon A Savage; Renee A Reijo Pera; Steven E Artandi
Journal:  Nature       Date:  2011-05-22       Impact factor: 49.962

10.  TPP1 OB-fold domain controls telomere maintenance by recruiting telomerase to chromosome ends.

Authors:  Franklin L Zhong; Luis F Z Batista; Adam Freund; Matthew F Pech; Andrew S Venteicher; Steven E Artandi
Journal:  Cell       Date:  2012-08-03       Impact factor: 66.850

View more
  6 in total

1.  Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism.

Authors:  Kunitoshi Chiba; Franziska K Lorbeer; A Hunter Shain; David T McSwiggen; Eva Schruf; Areum Oh; Jekwan Ryu; Xavier Darzacq; Boris C Bastian; Dirk Hockemeyer
Journal:  Science       Date:  2017-08-17       Impact factor: 47.728

2.  Analysis of RNA conformation in endogenously assembled RNPs by icSHAPE.

Authors:  Lu Chen; Howard Y Chang; Steven E Artandi
Journal:  STAR Protoc       Date:  2021-04-28

3.  Genome-wide screens identify specific drivers of mutant hTERT promoters.

Authors:  Raghuvaran Shanmugam; Mert Burak Ozturk; Joo-Leng Low; Semih Can Akincilar; Joelle Yi Heng Chua; Matan Thangavelu Thangavelu; Giridharan Periyasamy; Ramanuj DasGupta; Vinay Tergaonkar
Journal:  Proc Natl Acad Sci U S A       Date:  2022-01-18       Impact factor: 12.779

Review 4.  Targeting Telomeres and Telomerase: Studies in Aging and Disease Utilizing CRISPR/Cas9 Technology.

Authors:  Andrew C Brane; Trygve O Tollefsbol
Journal:  Cells       Date:  2019-02-21       Impact factor: 6.600

5.  TIN2 Functions with TPP1/POT1 To Stimulate Telomerase Processivity.

Authors:  Alexandra M Pike; Margaret A Strong; John Paul T Ouyang; Carol W Greider
Journal:  Mol Cell Biol       Date:  2019-10-11       Impact factor: 5.069

Review 6.  CRISPR/Cas: A New Tool in the Research of Telomeres and Telomerase as Well as a Novel Form of Cancer Therapy.

Authors:  Mahendar Porika; Radhika Tippani; Gabriele Christine Saretzki
Journal:  Int J Mol Sci       Date:  2022-03-10       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.